This month, Senior Director of Personalized Healthcare Market Development at QIAGEN, Andrew Webb, sits down with GBI to discuss the exciting field of personalized medicine. In this interview, Andrew offers an insider look at new applications for molecular targeting, as well as the role this technology will play in pharmaceutical development in the future.

In this interview, Nisa Leung, partner of Qiming Ventures, shares her insights into how the venture capital landscape for the healthcare area has changed over the years, successful strategies for deal sourcing, and future trends in China’s healthcare market.

GBI sat down with Andreas Amrein, (outgoing) Head of Marketing and Sales Operations for Novartis China, to talk about pharmaceutical commercial sales and promotion-including a comparison of strategies and tactics used here to those in Western markets. Andreas also shares his opinions on medical rep-doctor relations, hospital listings, and the challenges of product launches in China.

John Oyler, founder of recently acquired life science CRO, BioDuro, sits down to discuss the motivation and process behind establishing and growing BioDuro, shares an insider's view of where the CRO industry as a whole is headed, and his future plans. John also offers advice to future would-be entrepreneurs on what it takes to be successful in China and beyond.

This month, GBI sat down with Joseph Tang, Director of Greater China for Smith & Nephew, and former head of Ethicon's global marketing team. In this interview, Joseph offers and in-depth overview of the role he played in attaining Johnson and Johnson's strong foothold in the China market, what it takes to be a successful startup, and possible effects the grassroots medical reform may have on the medical device industry in the future.

Interview with David Pieroni, Managing Director of Automation Quality Solutions (AQS). In this interview David discusses the different GXP regimes in China and overseas and challenges regarding quality assurance and compliance in China. David touches on the CRO, pharmaceutical, API, and device industries, and what to expect in the QA/QC area in China moving forward.

This month, GBI sits down with Dr. Sean Hu, the CEO and Chairman of Beike Biotechnology. In this interview, Dr. Hu discusses the motivation behind his commitment to stem-cell research as well as Beike's current research and clinical application status. He offers a detailed outline of Beike's business model and its future plans as the frontrunner in this up and coming industry.

In this interview IP experts Mark Cohen and Tony Chen shared their deep cumulative experiences from both the policy and practice perspective. In addition to broad patent and trademark issues, Mark and Tony explained the inventor's rights portions of the new patent law, explain the use of China to avoid platform technology patents, and discussed the outlook and forces for change in China's IP regime.

In this interview, Philip Xiao, the co-founder and CDO of Profex Inc, discusses such topics as Profex's struggle to grow from a small startup into a major player in China's dermatology market, the unique challenges facing Profex, anticipated effects of the new medical reform, and the company's future plans.

In this interview, Victor enlightens us on Qiagen's China products and services, the possible impact of the nation's healthcare reform on the molecular diagnostics sector, and the competitive landscape in Qiagen's business segments. Victor also addresses the company’s strategic plan for Asia as well as its past China acquisitions and the challenges associated with integrating those businesses

Interview with Carl Firth, Head of Asia Healthcare at Bank of America-Merrill Lynch. Carl analyzes China’s deal landscape for healthcare, the current investor environment, M&A appetites of both multinationals and domestics, and gives his observations of changes in the sector that have occurred over the past 12 to 18 months.

Interview with Ben Avancena, General Manager of Johnson & Johnson Medical (China) and international vice president for Johnson & Johnson's medical diagnostics division. In this interview, Ben discusses the highlights and challenges of being the GM of a multinational medical device company in China, the impact of the new healthcare reforms on the medical device and diagnostics sector, and strategies for multinational and domestic medical device companies going forward in China.

Interview with Sheldon Dorenfest, CEO of the Dorenfest Group, an investment and consulting firm focused on health care systems improvement. In this interview, Sheldon, an internationally recognized authority on healthcare I.T., expands on the positives and negatives of the Chinese healthcare system, the status of I.T. in healthcare institutions, and the I.T. resources currently needed by the nation’s physicians. Sheldon also discusses the entry of multinational I.T. providers, such as IBM and Microsoft, to the H.I.T. market and regulatory roadblocks to future progression of the sector.

Interview with Arthur C. Mok, partner at Hogan & Hartson's Shanghai office. In this interview, Arthur shares his insights on the current deal environment in China's healthcare industry. He discusses the impact of the global economic crisis on investment and important covenants in acquisition and licensing deals in China.

Interview with Dr. Jonathan Seah, former CEO of ParkwayHealth China. ParkwayHealth is one of the largest providers of private healthcare in Asia and China. In this interview, Jonathan discusses Parkway's strategy and approach in the mainland; the impact of the new medical reforms; and the past, present, and future of private healthcare in China. He also shares his plans for his latest venture.

In this interview, Reto outlines his experience with Schwarz Pharma, his drive to create and expand RxMidas, and the key role of product sourcing strategies in to specialty pharmaceutical companies. Reto also touches on medical reform, his experience with distribution, the company’s focus on CNS and cardiovascular disease, and his vision for the company.

In this interview Eric reflects on his 20 year experience in China, the development of the distribution industry and Zuellig's special role in the value chain. Eric shares his thoughts on M&A, consolidation, vertical integration, and the future of distribution in China's rapidly changing landscape.

In this interview, YuWen discusses the progress BioBay has made in attracting companies, the status of its venture fund, the competitive landscape for biotech zones, and the challenges such zones face in developing the industry. She highlighted the park’s progresses and how she measures success.

Interview with David Preston, former China General Manager of Sanofi-aventis In this interview, Dave provided practical and strategic advice to pharmaceutical companies, especially those focused on China’s growing cancer market. He highlighted execution, pricing, and reimbursement issues and illuminated the importance of key hospitals and biologics.

Jeff Schultz, Managing Director of China's R&D-based Pharmaceutical Association Committee (RDPAC), expands on the role of RDPAC in China's pharmaceutical industry, current concerns of RDPAC's members, and his take on the status of healthcare reform, pricing, and tendering.

Interview with Dr. Allan Liu, Director of Business Development for Fosun Pharma, a major publicly listed domestic pharmaceutical company with business lines spanning therapeutics, diagnostics, and retail pharmacy. In this interview Allan discusses how Fosun uncovers business opportunities, and the company's areas of interest for licensing. He also gives an overview of the challenges facing the domestic pharmaceutical industry, including the struggle to develop in-house innovative R&D capabilities.

In this interview, Mark discusses how he founded and grew Excel Pharmastudies into one of the leading CRO's in China. Mark also addressed opportunities and challenges for big pharma and biotech looking to conduct clinical trials in China. He specifically touches on chemical vs. biologic products, and the rapidly changing competitive landscape for clinical trials providers in China.

Hutchison Medipharma is Shanghai-based pioneer in new drug discovery. In this interview, Samantha discusses the genesis of Medipharma, the company's leading products, progress in clinical trials, high profile deals with Lilly and others, and the current corporate structure. Samantha also elaborates on the company's patent estate and how Medipharma protects its small molecule, mixture, and extract candidates.

This month GBI talked XianPing Lu, co-founder and president of Chipscreen Biosciences. Based in Shenzhen, Chipscreen is one of China's true drug discovery pioneers, having developed a platform technology and successfully driving several drug candidates into preclinical and clinical testing. In this interview, Dr. Lu discusses the founding of the company, its expanding pipeline, and the value of partnering with multinationals. He also touches on Chipscreen's plans for an IPO on China’s nascent NASDAQ-like board and strategy for commercialization of its late stage candidates.

This month GBI talked with Peter Zhang, CEO of GenePharma. GenePharma is a leading company in China's RNA industry. Peter touched the process of starting a biotech in China, challenges in financing and reaching overseas markets, and the state of China's RNA research. He also explained the reasons for the company’s move to Suzhou’s nascent BioBay from Shanghai's ZhangJiang high technology park.